^
Association details:
| Biomarker: | QKI-RAF1 fusion |
|---|---|
| Cancer: | Spindle Cell Sarcoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sustained Response to the Mitogen-Activated Extracellular Kinase Inhibitor Trametinib in a Spindle Cell Sarcoma Harboring a QKI-RAF1 Gene Fusion
Published date:
01/20/2022
Excerpt:
...a case of recently described spindle cell tumor displaying a QKI-RAF1 gene fusion resistant to standard cytotoxic chemotherapy. The use of the mitogen-activated extracellular kinase (MEK) 1 and 2 inhibitor trametinib yielded clinical benefit and an absence of progression for 10 months...With secondary resistance to conventional multiagent chemotherapy, the use of the MEK1/2 inhibitor trametinib induced a prolonged metabolic response and clinical benefit.
DOI:
10.1200/PO.21.00303 JCO Precision Oncology
